Wells Fargo analyst Derek Archila downgraded aTyr Pharma (ATYR) to Equal Weight from Overweight with a $1 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma downgraded to Neutral from Buy at Lucid Capital
- aTyr Pharma downgraded to Hold from Buy at JonesResearch
- Hold Rating Issued for aTyr Pharma Amid Uncertainty Over Efzofitimod’s Trial Results and Future
- aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
- aTyr Pharma downgraded to Market Perform from Outperform at Leerink